Exelixis
EXEL
#1695
Rank
โ‚ฌ9.48 B
Marketcap
33,21ย โ‚ฌ
Share price
0.52%
Change (1 day)
73.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : โ‚ฌ2.16 Billion

According to Exelixis's latest financial reports the company has โ‚ฌ2.16 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚ฌ2.04 B-11.72%
2022-12-31$โ‚ฌ2.31 B18.85%
2021-12-31$โ‚ฌ1.95 B27.77%
2020-12-31$โ‚ฌ1.52 B1.51%
2019-12-31$โ‚ฌ1.50 B33.73%
2018-12-31$โ‚ฌ1.12 B373.86%
2017-12-31$โ‚ฌ0.23 B179.69%
2016-12-31$โ‚ฌ84.91 M-165.94%
2015-12-31$-โ‚ฌ0.13 Billion36.39%
2014-12-31$-โ‚ฌ94.42 Million-296.85%
2013-12-31$โ‚ฌ47.96 M-78.6%
2012-12-31$โ‚ฌ0.22 B221.11%
2011-12-31$โ‚ฌ69.78 M-140.66%
2010-12-31$-โ‚ฌ0.18 Billion50.21%
2009-12-31$-โ‚ฌ0.12 Billion183.96%
2008-12-31$-โ‚ฌ40.25 Million-168.72%
2007-12-31$โ‚ฌ58.56 M-14.72%
2006-12-31$โ‚ฌ68.67 M41.98%
2005-12-31$โ‚ฌ48.36 M29.48%
2004-12-31$โ‚ฌ37.35 M-70.88%
2003-12-31$โ‚ฌ0.12 B-23.78%
2002-12-31$โ‚ฌ0.16 B-37.35%
2001-12-31$โ‚ฌ0.26 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚ฌ17.16 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ74.60 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ42.48 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ16.39 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ7.17 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ66.88 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ88.24 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.67 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ27.5 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA